Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood-Based Immune Signal Could Reveal Lung Cancer Risk Before Tumors Develop

By LabMedica International staff writers
Posted on 09 Oct 2026

Lung cancer remains difficult to detect before symptoms appear, when advanced disease is harder to treat. More...

In the U.K., about 32,800 people die from lung cancer each year, and only 11.1% of those diagnosed are predicted to survive 10 years or more. Earlier identification of high-risk individuals remains a major diagnostic challenge. To support earlier risk detection, new findings demonstrate a blood-based immune signal that may indicate lung cancer risk years before a tumor develops.

University College London (UCL) researchers identified a preinvasive regulatory T cell axis linked to lung cancer interception. The work used prototype blood tests to follow what the researchers described as an immune “fog.” This signal involved regulatory T cells, or Tregs, which are specialized immune cells that can hold back other immune cells and pause their activity. The buildup of Tregs occurred months or years before cancer developed.

The team studied blood and tissue samples from people enrolled in long-running lung cancer surveillance and screening studies. Similar processes were also analyzed in mice to examine how lung cancer precursors, described as precancers or lesions, can develop into full tumors. The study found that monitoring Treg levels could help identify people at increasing risk of lung cancer or patients with an early form of the disease.

The researchers also examined whether targeted cancer drugs could reverse and disperse the Treg “fog.” A drug targeting specific immune processes reversed the immune-suppressing effect of Tregs. In laboratory experiments, this approach halved the proportion of animals that developed lung tumors and prevented the formation of all large tumors. The findings were published in Nature on October 7, 2026.

“This study provides valuable new insight into the early stages of lung cancer development. By identifying mechanisms that could both signal increased risk and offer opportunities for intervention, this research highlights the potential of discovery science to underpin new approaches to cancer prevention and early detection,” said Dr. Charlotte Durkin, associate director of molecular and cellular medicine at MRC.

Related Links
University College London 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.